Precision Medicine in Oncology® | Specialty

Making EGFR-Positive NSCLC a Chronic Disease

November 20th 2014

Team Approach to Lung Cancer Care Is Essential

November 20th 2014

Reconsideration of Gefitinib in EGFR-Mutant NSCLC

November 20th 2014

Treating Acquired Resistance to TKIs in NSCLC

November 20th 2014

Dosing Strategies for Managing TKI-Related Side Effects

November 20th 2014

Patient-reported Outcomes with TKIs

November 20th 2014

Frontline Afatinib in EGFR-Mutant NSCLC

November 20th 2014

Frontline Treatment of Advanced NSCLC

November 20th 2014

Recommended Mutation Testing in Lung Cancer

November 20th 2014

Lung Cancer Treatment on Brink of New Molecular Era

November 10th 2014

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Dr. Lynch Discusses Resistance to EGFR TKIs in Lung Cancer

November 8th 2014

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

New Research Focuses on Personalized Treatments in Ovarian Cancer

November 6th 2014

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

November 1st 2014

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

October 31st 2014

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014